Plasmalogens for Health & Longevity

Created on 11/08/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Plasmalogens are membrane fats the body makes itself, sold as dietary supplements to people interested in brain health: tiny daily amounts of purified scallop or sea squirt extracts, or much larger doses of oils the body converts into plasmalogens. Small company-run studies reported better memory, but the largest study found no overall benefit. Safety over a few months is reassuring at the doses studied; long-term safety is unknown. (Full Review)

Protocol

Standard marine extract dose
1 mg/day
Purified scallop plasmalogen, split as 0.5 mg twice daily, for 24 weeks
Alternative marine doses
1–2 mg/day
1 mg/day once daily for 12 weeks; 1 mg/day sea squirt extract; 2 mg/day for 4 weeks
Precursor approach
Labeled 900 mg per 2-capsule serving
DHA-precursor oils, whose dosing report was retracted; shark liver oil alkylglycerols: 4 g/day
Time to effect
Memory and cognitive performance
8–12 weeks
Memory differences appeared in trials of forgetful, healthy adults
Mood and mental fatigue
4 weeks
Mood changes appeared in athletes
Quality of life in Parkinson's disease
24 weeks
Quality-of-life scores improved in an open-label series without a placebo group

Benefits

Contraindications
  • People with scallop, mollusk, or sea squirt allergy (marine-derived extracts)
  • People with active cancer
  • People with liver disease (high-dose precursor oils)
Key Interactions
  • Statins (rosuvastatin studied; atorvastatin and simvastatin untested)
  • Krill oil
  • Shark liver oil (alkylglycerols)
  • Myo-inositol
Theoretical (inferred from mechanism)
  • Anticoagulants and antiplatelet drugs (warfarin, aspirin)
  • Over-the-counter NSAIDs (ibuprofen, naproxen)
  • Orlistat (Alli, Xenical)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Gastrointestinal effects; liver injury with precursors; allergic reactions in seafood-sensitive people
  • Speculative: Ferroptosis sensitization; support of tumor lipid metabolism

Monitoring

Marker Target Why
Blood ethanolamine plasmalogen (plasma or red-cell PlsEtn) No established target; track change from own baseline Marker expected to change
ALT 7–55 U/L (standard reference range) Safety check on precursor use
AST 8–48 U/L (standard reference range) Safety check on precursor use
Triglycerides (shark liver oil or alkylglycerol users) Below 150 mg/dL (standard reference range) Expected to change with alkylglycerol precursors
Cognitive test score (e.g., MoCA or Cognitrax) No established target; track change from own baseline Memory outcome

Cadence: Baseline before starting; on precursor oils, liver enzymes at 4–8 weeks and then every 6 months; lipid panel at 8–12 weeks; cognitive testing at 12 weeks and then every 6–12 months

Qualitative Assessment

  • Everyday memory, such as recalling names and appointments
  • Mental fatigue and concentration during long tasks
  • Mood, irritability, and sense of vigor
  • Sleep quality and morning alertness
  • Digestive tolerance, especially with oil-based precursors